Cytokinetics, Inc. is expected to release top-line data from the Phase III METEORIC-HF study of omecamtiv mecarbil, a selective cardiac myosin activator, by the end of April. The METEORIC-HF study has enrolled 276 heart failure patients with reduced ejection fraction and decreased exercise tolerance and measures the primary endpoint of change in peak oxygen uptake on cardiopulmonary exercise testing from baseline to week 20.
The development of omecamtiv has been hindered by obstacles, with the candidate showing only a slim efficacy benefit in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?